专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

HRP20041147A2 CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONISTS 未知
公开(公告)号：HRP20041147A2
公开(公告)日：2005-08-31
申请号：HRP20041147
申请日：2004-12-01
申请人： SQUIBB BRISTOL MYERS CO , ORATION
发明人： CHATURVEDULA PRASAD V , CHEN LING , CIVIELLO RITA , CONWEY CHARLES MARK , DEGNAN ANDREW P , GENE DUBOWCHIK , KARAGEORGE GEORGE N , LUO GUANGLIN , MACOR JOHN E , POINDEXTER GRAHAM , VIG SHIKHA , HAN XIAOJUN
IPC分类号： C07D487/04 , A01K67/027 , A61K31/438 , A61K31/4427 , A61K31/4545 , A61K31/496 , A61K31/517 , A61K31/519 , A61K31/527 , A61K31/537 , A61K31/5377 , A61K49/00 , A61P9/00 , A61P11/00 , A61P11/06 , A61P15/12 , A61P17/00 , A61P25/00 , A61P25/04 , A61P25/06 , A61P29/00 , C07D401/14 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D471/04 , C07D471/10 , C07D487/14 , C07D487/22 , C07D491/10 , C07D491/113 , C07D498/10 , C07D519/00 , C12N15/85 , G01N33/566
摘要： The present invention relates to in vivo non-terminal method of identifying anti-migraine compounds.

2. 发明公开

EP1539766A4 CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONISTS 有权
标题翻译：降钙素相关肽受体拮抗剂
公开(公告)号：EP1539766A4
公开(公告)日：2007-08-08
申请号：EP03736721
申请日：2003-05-27
申请人： SQUIBB BRISTOL MYERS CO
发明人： CHATURVEDULA PRASAD V , CHEN LING , CIVIELLO RITA , CONWAY CHARLES MARK , DEGNAN ANDREW P , DUBOWCHIK GENE M , HAN XIAOJUN , KARAGEORGE GEORGE N , LUO GUANGLIN , MACOR JOHN E , POINDEXTER GRAHAM , VIG SHIKHA
IPC分类号： C07D487/04 , A01K67/027 , A61K31/438 , A61K31/4427 , A61K31/4545 , A61K31/496 , A61K31/517 , A61K31/519 , A61K31/527 , A61K31/537 , A61K31/5377 , A61K49/00 , A61P9/00 , A61P11/00 , A61P11/06 , A61P15/12 , A61P17/00 , A61P25/00 , A61P25/04 , A61P25/06 , A61P29/00 , C07D401/14 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D471/04 , C07D471/10 , C07D487/14 , C07D487/22 , C07D491/10 , C07D491/113 , C07D498/10 , C07D519/00 , C12N15/85 , G01N33/566
CPC分类号： A01K67/0275 , A01K2207/15 , A01K2217/00 , A01K2217/05 , A01K2227/106 , A01K2267/0306 , A61K49/0008 , C07D401/14 , C07D405/14 , C07D409/14 , C07D471/10 , C07D487/04 , C07D487/14 , C07D491/10 , C12N15/8509 , G01N33/566 , G01N2500/10 , G01N2800/2807
摘要： The presnt invention relates to compounds of Formula (I), as antagonists of calcitonin gene-related peptide receptors ("CGRP-receptor"), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and their use in therapy for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.

3. 发明专利

AU2003237255B2 Calcitonin gene related peptide receptor antagonists 未知
公开(公告)号：AU2003237255B2
公开(公告)日：2009-12-17
申请号：AU2003237255
申请日：2003-05-27
申请人： SQUIBB BRISTOL MYERS CO
发明人： KARAGEORGE GEORGE N , CHATURVEDULA PRASAD V , VIG SHIKHA , HAN XIAOJUN , CHEN LING , POINDEXTER GRAHAM , CIVIELLO RITA , DUBOCHIK GENE M , MACOR JOHN E , CONWAY CHARLES MARK , DEGNAN ANDREW P , LUO GUANGLIN
IPC分类号： A01K67/027 , C07D487/04 , A61K31/438 , A61K31/4427 , A61K31/4545 , A61K31/496 , A61K31/517 , A61K31/519 , A61K31/527 , A61K31/537 , A61K31/5377 , A61K49/00 , A61P9/00 , A61P11/00 , A61P11/06 , A61P15/12 , A61P17/00 , A61P25/00 , A61P25/04 , A61P25/06 , A61P29/00 , C07D401/14 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D471/04 , C07D471/10 , C07D487/14 , C07D487/22 , C07D491/10 , C07D491/113 , C07D498/10 , C07D519/00 , C12N15/85 , G01N33/566
摘要： The present invention relates to in vivo non-terminal method of identifying anti-migraine compounds.

4. 发明专利

GEP20074231B CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONISTS 未知
公开(公告)号：GEP20074231B
公开(公告)日：2007-11-12
申请号：GEAU2003008575
申请日：2003-05-27
申请人： SQUIBB BRISTOL MYERS CO
发明人： CHATURVEDULA PRASAD V , CHEN LING , CIVIELLO RITA , CONWAY CHARLES MARK , DEGNAN ANDREW P , DUBOWCHIK GENE M , QSIAOIUN HANI , KARAGEORGE GEORGE N , LUO GUANGLIN , MACOR JOHN E , POINDEXTER GRAHAM , VIG SHIKHA
IPC分类号： C07D487/04 , C07D487/14 , A01K67/027 , A61K31/438 , A61K31/4427 , A61K31/4545 , A61K31/496 , A61K31/517 , A61K31/519 , A61K31/527 , A61K31/537 , A61K31/5377 , A61K49/00 , A61P9/00 , A61P11/00 , A61P11/06 , A61P15/12 , A61P17/00 , A61P25/00 , A61P25/04 , A61P25/06 , A61P29/00 , C07D401/14 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D471/04 , C07D471/10 , C07D487/22 , C07D491/10 , C07D491/113 , C07D498/10 , C07D519/00 , C12N15/85 , G01N33/566
摘要： A compound of Formula (I) (values of A, V, D, Q, U, G, E, J, m and n are provided in the description), a pharmaceutical compositions comprising them and use thereof for treatment of migraine.

6. 发明专利

AU2003237255A1 CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONISTS 未知
公开(公告)号：AU2003237255A1
公开(公告)日：2003-12-22
申请号：AU2003237255
申请日：2003-05-27
申请人： SQUIBB BRISTOL MYERS CO
发明人： CHATURVEDULA PRASAD V , CHEN LING , CIVIELLO RITA , CONWAY CHARLES MARK , DEGNAN ANDREW P , DUBOWCHIK GENE M , HAN XIAOJUN , KARAGEORGE GEORGE N , LUO GUANGLIN , MACOR JOHN E , POINDEXTER GRAHAM , VIG SHIKHA
IPC分类号： C07D487/04 , A01K67/027 , A61K31/438 , A61K31/4427 , A61K31/4545 , A61K31/496 , A61K31/517 , A61K31/519 , A61K31/527 , A61K31/537 , A61K31/5377 , A61K49/00 , A61P9/00 , A61P11/00 , A61P11/06 , A61P15/12 , A61P17/00 , A61P25/00 , A61P25/04 , A61P25/06 , A61P29/00 , C07D401/14 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D471/04 , C07D471/10 , C07D487/14 , C07D487/22 , C07D491/10 , C07D491/113 , C07D498/10 , C07D519/00 , C12N15/85 , G01N33/566
摘要： The present invention relates to in vivo non-terminal method of identifying anti-migraine compounds.

7. 发明专利

AR046788A1 ANTAGONISTAS DEL RECEPTOR PEPTIDO RELACIONADO CON EL GEN DE CALCITONINA 未知
公开(公告)号：AR046788A1
公开(公告)日：2005-12-21
申请号：ARP040104530
申请日：2004-12-03
申请人： SQUIBB BRISTOL MYERS CO
发明人： CHATURVEDULA PRASAD V , CIVIELLO RITA , CONWAY CHARLES MARK , DEGNAN ANDREW P , DUBOWCHIK GENE M , HAN XIAOJUN , MACOR JOHN E , POINDEXTER GRAHAM , TORA GEORGE , VIG SHIKHA , CHEN LING , LUO GUANGLIN , JIAN XIANG JUN J , KARAGEORGE GEORGE N
IPC分类号： A61K31/495 , A61K31/50 , A61K31/517 , A61K31/52 , A61K31/535 , A61K31/54 , A61K31/55 , A61P25/06 , C07D209/08 , C07D213/64 , C07D221/00 , C07D231/56 , C07D239/00 , C07D239/80 , C07D243/10 , C07D249/18 , C07D263/58 , C07D265/00 , C07D285/00 , C07D317/00 , C07D401/06 , C07D401/12 , C07D403/12 , C07D403/14 , C07D405/14 , C07D413/12 , C07D417/14 , C07D471/04 , C07D471/10 , C07D491/10 , C07D498/10
摘要： Compuestos de fórmula (1) como antagonistas de los receptores péptidos relacionados con el gen de calcitonina (''receptor CGRP''), composiciones farmacéuticas que los comprenden, métodos para su identificación, métodos de tratamiento con su uso, y su uso en terapia para el tratamiento de la vasodilatación neurogénica, inflamación neurogénica, migrana y otros dolores de cabeza, lesión térmica, choque circulatorio, sofocaciones asociadas con la menopausia, enfermedades inflamatorias de las vías aéreas, tales como asma y enfermedad pulmonar obstructiva crónica (COPD) y otras condiciones, el tratamiento de las cuales se puede efectuar por el antagonismo de los receptores CGRP. Reivindicación 1: Un compuesto caracterizado porque es seleccionados del grupo que consiste en: éster de metilo del ácido (ñ)-3-(3-ciano-1H-indol-5-il)-2-{[4-(2-oxo-1,4-dihidro-2H-quinazolin-3-il) -piperidin-1-carbonil]-amino}-propiónico; [2-[1,4']bipiperidinil-1'-il-1-(3-ciano-1H-indol-5-il-metil)-2- oxo-etil]-amida del ácido (ñ)-4-(2-oxo-1,4-dihidro-2H-quinazolin-3-il)-piperidin-1-carboxílico; [2-[1,4']bipiperidinil-1'-il-1(3-ciano-7-metil-1H-indol-5-il-metil)-2-oxo-etil]-amida del ácido (ñ)-4-(2-oxo-1,4-dihidro-2H-quinazolin-3-il)-piperidin- 1- carboxílico; éster de metilo del ácido (ñ)-3-(7-isopropil-1H-indazol-5-il)-2-{[4-(2-oxo-1,4-dihidro-2H-quinazolin-3-il)-piperidin-1-carbonil]-amino}-propiónico; [2-[1,4']bipiperidinil-1'-il-1(7-isopropil-1H-indazol-5-il-metil)-2-oxo-etil]-amida del ácido (ñ)-4-(2-oxo-1,4-dihidro-2H-quinazolin-3-il)-piperidin-1-carboxílico; [2-[1,4']bipiperidinil-1'-il-1(7-etil-1H-indazol-5-il-metil)-2-oxo-etil]-amida del ácido (ñ)-4-(2-oxo-1,4-dihidro-2H-quinazolin-3-il)-piperidin-1-carboxílico; [2- [1,4']bipiperidinil-1'-il-1(7-metil-1H-indazol-5-il-metil)-2-oxo-etil]-amida del ácido (ñ)-4-(2,2-dioxo-1,4-dihidro-2H-2l6-benzo[1,2,6]tiadiazin-3-il)-piperidin-1-carboxílico; [2-[1,4']bipiperidinil-1'-il-1(7-metil-3-metil-1H-indazol-5-il- metil)-2- oxo-etil]-amida del ácido (ñ)-4-(2,2-dioxo-1,4-dihidro-2H-2l6-benzo[1,2,6]tiadiazin-3-il)-piperidin-1-carboxílico; éster de metilo del ácido (ñ)-2-[4-(6-ciano-2-oxo-1,4-dihidro-2H-quinazolin-3-il)-piperidin-1-carbonil]-amino]-3-(7-metil-1H-indazol-5- il)-propiónico; {2-[1,4'] bipiperidinil-1'-il-(7-metil-1H-indazol-5-il metil)-2-oxo-etil}-amida del ácido (ñ)-4- (6-ciano-2-oxo-1,4-dihidro-2H-quinazolin-3-il)-piperidin-1-carboxílico; {2- [1,4'] bipiperidinil-1'-il-1-(7-metil- 1H-indazol-5-ilmetil)- 2-oxo-etil}-amida del ácido (ñ)-4-(2-oxo-1,2,4,5-tetrahidro-benzo [d][1,3]diazepin-3-il-1-carboxílico; {2-[1,4'] bipiperidinil-1'-il-1- (7-metil-1H-indazol-5-il metil)-2-oxo-etil}-amida del ácido (ñ)-4-(6-hidroxi-2-oxo- 1,4-dihidro-2H -quinazolin-3- il)-piperidin-1-carboxílico; {2- [1,4']bipiperidinil-1'-il-1-(7-metil-1H-indazol-5-il metil)-2-oxo-etil}-amida del ácido (ñ)-4-(8-metoxi-2-oxo-1,4-dihidro-2H-quinazolin-3-il)-piperidin-1-carboxílico; {2-[1,4']bipiperidinil-1'-il-1-(7-metil-1H- indazol-5-ilmetil)-2-oxo-etil}-amida del ácido (ñ)-4-(8-cloro-2-oxo-1,4-dihidro-2H-quinazolin-3-il)-piperidin-1-carboxílico; (ñ)-N-(3- (7-etil-3-metil-1 H-indazol-5-il)-1-oxo-1-(4-(piperidin-1-il)piperidin- 1-il)propan-2-il)-2',3'-dihidro-2'- oxoespiro-(piperidin-4,4'-quinazolin)-1-carboxamida; (ñ)-N-(3- (7-etil-3-metil-1H-indazol-5-il)-1-oxo-1-(4-(piperidin-1-il)piperidin-1-il)propan-2-il) -2,4-dihidro-2'-oxoespiro-(piperidin-4,4'-1H-benzo [d][1,3] oxazin)-1-carboxamida;(ñ)-N-(3- (7- etil-1H-indazol-5-il)-1-(6,7-dihidro-1H-pirazol [4,3-c]piridin-5(4H) -il)-1-oxopropan-2-il)-4-(1,2-dihidro-2-oxoquinazolin-3(4H)-il)piperidin-1-carboxamida; (ñ)-N-(3-(7-etil-1H-indazol-5-il)-1-(6,7-dihidro-7,7- dimetil-1H-pirazol [4,3-c]piridin- 5(4H)-il)-1-oxopropan-2-il)-4-(1,2-dihidro-2-oxoquinazolin-3(4H)-il)piperidin-1-carboxamida; (ñ)-metil 2-(4-(8-fluoro-1,2-dihidro-2-oxoquinazolin-3(4H)-il)piperidin-1-carboxamida)-3-(7-metil-1H-indazol-5- il)propanoato; (ñ)-4-(8-fluoro-1,2-dihidro-2- oxoquinazolin-3(4H)-il)-N-(3-(7-metil-1H-indazol-5-il)-1-oxo-1-(4-(piperidin-1-il)piperidin-1-il)propan-2-il)piperidin-1-carboxamida; (ñ)-4- (8-fluoro-1,2-dihidro-2-oxoquinazolin-3(4H)-il)-N-(3-(7- metil-1H-indazol-5-il)-1-oxo-1-(4-fenilpiperazin-1- il)propan-2-il)piperidin-1-carboxamida; (ñ)-4-(8-fluoro-1,2-dihidro-2-oxoquinazolin-3(4H)-il)-N(1-(4-(4-fluorofenil)piperazin-1-il)-3-(7-metil-1H-indazol-5-il)-1-oxopropan-2-il)piperidin-1- carboxamida; (ñ)-4-(8-fluoro-1,2-dihidro-2-oxoquinazolin- 3(4H)-il)-N-(1-(4-(2-fluorofenil)piperazin-1-il)-3- (7-metil-1H-indazol-5-il)-1-oxopropan-2-il)piperidin-1-carboxamida; (ñ)-4-(8-fluoro-1,2-dihidro-2-oxoquinazolin-3(4H)-il)-N-(3-(7-metil- 1H-indazol-5-il)-1-oxo-1-(4-o-tolilpiperazin-1-il)propan-2- il)piperidin-1-carboxamida; (ñ)-metil 2-(4-(8-fluoro-1,2-dihidro-2-oxoquinazolin-3(4H)-il)piperidin-1-carboxamida)-3-(7-etil-3-metil-1H-indazol-5-il)propanoato; (ñ)-N-(3-(7-etil-3-metil- 1H-indazol-5-il)-1-oxo-1-(4-(piperidin-1-il)piperidin-1- il)propan-2-il)-4-(8-fluoro-1,2-dihidro-2-oxoquinazolin-3(4H)-il)piperidin-1- carboxamida; (R)-N-((R)-3-(2-oxo-2,3-dihidro-benzooxazol-6-il)-1-oxo-1-(4-piperidin-1-il)piperidin-1-il)propan-2- il)-4-(8-fluoro-1,2-dihidro-2-oxoquinazolin-3(4H)- il)piperidin-1-carboxamida; (ñ)-N-(3- (7-metil-1 H-indazol-5-il)-1-oxo-1-(4-(piperidin-1-il)piperidin-1-il)propan-2-il)-8'-fluoro-2',3'-dihidro-2'-oxoespiro-(piperidin-4,4'-quinazolin)-1- carboxamida; (ñ)-4-(8-fluoro-1,2-dihidro-2,4-dioxoquinazolin- 3(4H)-il)-N-(3-(7-metil-1H-indazol-5-il)-1-oxo-1-(4-(piperidin-1-il)piperidin-1-il) propan-2-il)piperidin-1-carboxamida; N-((R)-3-(2-(trifluorometil)-1H-benzo[d]imidazol-5-il)-1-oxo-1-(4- (piperidin-1-il)piperidin-1-il)propan-2-il)-4-(1,2-dihidro-2- oxoquinazolin-3(4H)-il)piperidin-1-carboxamida; N-((R)-1-(dimetilcarbamoil)-2-(2-(trifluorometil)-1H-benzo[d]imidazol-5-il)etil)-4-(1, 2-dihidro-2-oxoquinazolin-3(4H)-il)piperidin-1- carboxamida; (R)-metil 2-(4-(1,2-dihidro-2-oxoquinazolin-3(4H)- il)piperidin-1-carboxamido)-3-(2,3-dihidro-2-oxo-1H-benzo[d]imidazol-6-il) propanoato; N-((R)-3-(2,3-dihidro-2-oxo-1H-benzo[d]imidazol-6-il)-1-oxo-1(4-piperidin-1-il)piperidin-1- il)propan-2-il)-4-(1,2-dihidro-2-oxoquinazolin-3(4H)-il)piperidin-1- carboxamida; N-((R)-1-(dimetilcarbamoil)-2-(2,3-dihidro-2-oxo-1H-benzo[d]imidazol-6-il)etil)-4-(1,2-dihidro-2-oxoquinazolin-3(4H)-il)piperidin-1-carboxamida; N-((R)-3-(2,3-dihidro-2- oxo-1H-benzo[d]imidazol-6-il)-1-oxo-1(4-piperidin-1-il)piperidin-1- il)propan-2-il)-4-(2',3'-dihidro-2'-oxoespiro(piperidin-4,4'-(1H)- quinazolin)carboxamida; 4- (1,2-dihidro-2,4-dioxoquinazolin-3(4H)-il)-N-((R)-3-(7-metil-1H-benzo[d] [1,2,3]triazol- 5-il)-1-oxo-1-(4-(piperidin-1-il)piperidin-1-il)propan-2- il)piperidin-1-carboxamida; [2-(4-ciclohexil-piperazin-1-il)-2-oxo-1-(2-oxo-2,3-dihidro-benzooxazol-6-ilmetil)-etil]-amida del ácido (R)-4- (2-oxo-1,4-dihidro-2H-quinazolin-3-il)-piperidin-1- carboxílico; [2-(4-isopropil-piperazin-1-il)-2-oxo-1-(2- oxo-2,3-dihidro-benzooxazol-6-ilmetil)-etil]-amida del ácido (R)-4-(2-oxo-1,4-dihidro-2H-quinazolin-3-il)-piperidin-1-carboxílico; (R)-N-((R)-3-(2-oxo-2,3-dihidro-benzooxazol-6-il)-1-oxo-1-(4- (piperidin-1-il)piperidin-1-il)propan-2-il)-2,4-dihidro- 2'-oxoespiro-(piperidin-4,4'-1H-benzo[d][1,3]oxazin)-1-carboxamida; (R)-N-((R)-3-(2-oxo-2,3-dihidro-benzooxazol-6-il)-1-oxo-1-(4-(ciclohex-1-il)piperazin-1-il)propan-2-il)-2,4-dihidro-2'- oxoespiro-(piperidin-4,4'-1H- benzo[d][1,3]oxazin)-1- carboxamida; (R)-N ((R)-3-(2-oxo-2,3-dihidro-benzooxazol-6-il)-1-oxo-1-(4-(prop-2-il)piperazin-1-il)propan-2-il)-2,4-dihidro-2'-oxoespiro-(piperidin-4,4'-1H-benzo[d][1,3]oxazin)-1-carboxamida; (R)- N-((R)-3-(2-oxo-2,3-dihidro-benzooxazol-6-il)-1-oxo- 1-(4-(piperidin-1-il) piperidin-1-il)propan-2-il)-2, 4-dihidro-2'-oxoespiro-(piperidin-4,4'-1H-quinazolin)-1-carboxamida; (R)-N-((R)-3-(2-oxo-2,3-dihidro-benzooxazol-6-il)-1-oxo-1-(4-(ciclohex-1- il)piperazin-1-il)propan-2-il) -2,4-dihidro-2'- oxoespiro-(piperidin-4,4'-1H-quinazolin)-1-carboxamida; (R)-N-((R)-3-(2-oxo-2,3-dihidro-benzooxazol-6-il)-1-oxo-1-(4-(prop-2-il)piperazin-1-il)propan-2-il)-2,4-dihidro-2'-oxoespiro-(piperidin-4,4'-1H- quinazolin)-1-carboxamida; [2- [1,4']bipiperidinil-1'-il-1-(4-cloro-2-oxo-2,3-dihidro-benzooxazol-6-ilmetil)-2-oxo-etil]-amida del ácido (R)-4-(2-oxo-1,4-dihidro-2H-quinazolin-3-il)-piperidin-1-carboxílico; [2-[1,4']bipiperidinil-1'-il-1- (5-cloro-2- oxo-2,3-dihidro-benzooxazol-6- ilmetil)-2-oxo-etil]-amida del ácido (R)-4-(2-oxo-1,4-dihidro-2H-quinazolin-3-il)-piperidin-1-carboxílico; [2-[1,4']bipiperidinil-1'-il-1-(4-bromo-2-oxo-2,3-dihidro-benzooxazol-6-ilmetil)-2-oxo-etil]-amida del ácido (R)- 4-(2-oxo-1,4-dihidro-2H- quinazolin-3-il)-piperidin-1-carboxílico; [2-[1,4'] bipiperidinil-1'-il-1- (5-bromo-2-oxo-2,3-dihidro-benzooxazol-6-ilmetil)-2- oxo-etil]-amida del ácido (R)-4-(2-oxo-1,4-dihidro-2H-quinazolin-3-il)-piperidin-1-carboxílico; [2-[1,4']bipiperidinil-1'- il-1- (4-yodo-2-oxo-2,3-dihidro-benzooxazol-6-ilmetil)-2-oxo-etil]-amida del ácido (R)-4-(2-oxo-1,4-dihidro-2H-quinazolin-3-il)-piperidin-1-carboxílico; (ñ)-N-(1-bencil-2-hidroxi-etil)-2-(7-metil-1H-indazol-5-ilmetil)-4- oxo-4- [1',2'-dihidro-2'- oxoespiro-[4H-3',1-benzoxazin-4, 4'-piperidinil]-butiramida; (ñ)-N(1-Bencil-2-hidroxi-etil)-2- (7-metil-1H-indazol-5-ilmetil)-4-oxo-4-[4-(2-oxo-1,4-dihidro-2H-quinazolin-3-il)-piperidin-1-il]-butiramida; N'-{2-(7-metil-1H- indazol-5-ilmetil)-4-oxo-4- [4-(2-oxo-1,4-dihidro-2H-quinazolin-3-il)-piperidin-1-il]-butiril}-hidrazida del ácido (ñ)-fenil-acético; (ñ)-1-[1,4']bipiperidinil-1'-il-4-[4-(8-fluoro-2-oxo-1,4-dihidro-2H-quinazolin-3-il)-piperidin-1-il]-2-(7-metil- 1H-indazol-5-ilmetil)-butano- 1,4-diona; (ñ)-1- [1,4']bipiperidinil-1'-il-2- (7-metil-1H-indazol-5-ilmetil)-4-[2',3'-dihidro-2'-oxoespiro-(piperidin-4,4'-quinazolin]-butano-1,4-diona; (ñ)-1-(4-ciclohexil-piperazin-1-il)-2-[2-oxo-2-dihidro- benzooxazol-6-ilmetil]-4-[4-(2-oxo-1,4- dihidro-2H-quinazolin-3-il)-piperidin-1-il]-butano-1,4-diona; (ñ)-1- [1,4']bipiperidinil-1'-il-2-(2-oxo-2,3-d

8. 发明专利

RS52552B CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONISTS 未知
公开(公告)号：RS52552B
公开(公告)日：2013-04-30
申请号：YUP104004
申请日：2003-05-27
申请人： SQUIBB BRISTOL MYERS CO
发明人： DEGNAN ANDREW P , CHEN LING , DUBOWCHIK GENE M , HAN XIAOJUN , MACOR JOHN E , CHATURVEDULA PRASAD V , CIVIELLO RITA , CONWAY CHARLES MARK , KARAGEORGE GEORGE N , LUO GUANGLIN , POINDEXTER GRAHAM , VIG SHIKHA
IPC分类号： C07D487/04 , C07D487/14 , A01K67/027 , A61K31/438 , A61K31/4427 , A61K31/4545 , A61K31/496 , A61K31/517 , A61K31/519 , A61K31/527 , A61K31/537 , A61K31/5377 , A61K49/00 , A61P9/00 , A61P11/00 , A61P11/06 , A61P15/12 , A61P17/00 , A61P25/00 , A61P25/04 , A61P25/06 , A61P29/00 , C07D401/14 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D471/04 , C07D471/10 , C07D487/22 , C07D491/10 , C07D491/113 , C07D498/10 , C07D519/00 , C12N15/85 , G01N33/566
摘要： The present invention relates to in vivo non-terminal method of identifying anti-migraine compounds.

9. 发明专利

CA2487976C CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONISTS 未知
公开(公告)号：CA2487976C
公开(公告)日：2011-07-26
申请号：CA2487976
申请日：2003-05-27
申请人： SQUIBB BRISTOL MYERS CO
发明人： CHATURVEDULA PRASAD V , CHEN LING , CIVIELLO RITA , CONWAY CHARLES MARK , DEGNAN ANDREW P , DUBOWCHIK GENE M , HAN XIAOJUN , KARAGEORGE GEORGE N , LUO GUANGLIN , MACOR JOHN E , POINDEXTER GRAHAM , VIG SHIKHA
IPC分类号： C07D487/04 , C07D487/14 , A01K67/027 , A61K31/438 , A61K31/4427 , A61K31/4545 , A61K31/496 , A61K31/517 , A61K31/519 , A61K31/527 , A61K31/537 , A61K31/5377 , A61K49/00 , A61P9/00 , A61P11/00 , A61P11/06 , A61P15/12 , A61P17/00 , A61P25/00 , A61P25/04 , A61P25/06 , A61P29/00 , C07D401/14 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D471/04 , C07D471/10 , C07D487/22 , C07D491/10 , C07D491/113 , C07D498/10 , C07D519/00 , C12N15/85 , G01N33/566
摘要： The presnt invention relates to compounds of Formula (I), as antagonists of calcitonin gene-related peptide receptors ("CGRP-receptor"), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and their use in therapy for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.

10. 发明专利

AU2003237255B8 Calcitonin gene related peptide receptor antagonists 未知
公开(公告)号：AU2003237255B8
公开(公告)日：2010-01-07
申请号：AU2003237255
申请日：2003-05-27
申请人： SQUIBB BRISTOL MYERS CO
发明人： KARAGEORGE GEORGE N , CHATURVEDULA PRASAD V , VIG SHIKHA , HAN XIAOJUN , CHEN LING , POINDEXTER GRAHAM , CIVIELLO RITA , DUBOWCHIK GENE M , MACOR JOHN E , CONWAY CHARLES MARK , DEGNAN ANDREW P , LUO GUANGLIN
IPC分类号： A01K67/027 , C07D487/04 , A61K31/438 , A61K31/4427 , A61K31/4545 , A61K31/496 , A61K31/517 , A61K31/519 , A61K31/527 , A61K31/537 , A61K31/5377 , A61K49/00 , A61P9/00 , A61P11/00 , A61P11/06 , A61P15/12 , A61P17/00 , A61P25/00 , A61P25/04 , A61P25/06 , A61P29/00 , C07D401/14 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D471/04 , C07D471/10 , C07D487/14 , C07D487/22 , C07D491/10 , C07D491/113 , C07D498/10 , C07D519/00 , C12N15/85 , G01N33/566
摘要： The present invention relates to in vivo non-terminal method of identifying anti-migraine compounds.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式